Noninvasive Transcutaneous Glucometer Development
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
| Condition |
|---|
|
Healthy Prediabetic State (IGT) Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Cross-Sectional |
| Official Title: | Noninvasive Transcutaneous Glucometer Development |
| Estimated Enrollment: | 500 |
| Study Start Date: | December 2001 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
The feasibility of measuring blood glucose concentration in patients with diabetes mellitus using near infrared (NIR) spectroscopy and multivariate data analysis techniques has been established using general purpose, scientific-grade infrared spectrophotometers under the 90-049 UNM HRRC protocol. Now that the concept of painless, bloodless, and reagent-less clinical laboratory tests has been shown to be viable, the challenge is to bring this technology to the patients who need it. We must develop a device that is portable, affordable, and rugged - all while improving accuracy. We must also improve our understanding of the nature of glucose in whole, intact skin. Since the light beam cannot discriminate plasma glucose in skin blood vessels from glucose in the larger skin interstitial fluid space, the exact nature of the glucose in all tissue compartments contributing to the light-beam signal must be elucidated. The noninvasive measurement can be no more accurate than the reference measurement on which it was based. Finally, we have found that the accuracy of the noninvasive measurement also worsens as a function of time from the initial measurement. This effect is independent of instrumentation drift and is due to physical changes in the patient's skin such as variation of hydration, collagen, vascularity, glycation end-products, etc. To account for these sources of physiologic interference they must be evaluated independently and then compared to errors of the noninvasive predictions over time.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Those with Type 1 and 2 diabetes
Inclusion Criteria:
- 18 years of age or older
- Healthy
- Type I diabetics
- Type II diabetics
- Impaired glucose tolerance
Exclusion Criteria:
- Minor status (<18 years of age)
- Pregnant
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Jeff Way, InLight Solutions |
| ClinicalTrials.gov Identifier: | NCT01168076 History of Changes |
| Other Study ID Numbers: | ILS-01-007 |
| Study First Received: | July 21, 2010 |
| Last Updated: | July 21, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Prediabetic State Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on June 17, 2013